Prediction of Response to Adjuvant Chemotherapy in Premenopausal Lymph Node Positive Breast Cancer Patients with Morphometry, DNA Flow Cytometry and Her-2/Neu Oncoprotein Expression: Preliminary Results
- 30 April 1992
- journal article
- Published by Elsevier in Pathology - Research and Practice
- Vol. 188 (3) , 344-349
- https://doi.org/10.1016/s0344-0338(11)81215-x
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- The morphometric prognostic index is the strongest prognosticator in premenopausal lymph node-negative and lymph node-positive breast cancer patientsHuman Pathology, 1991
- Adjuvant Chemotherapy for Breast CancerPublished by American Medical Association (AMA) ,1985
- The value of morphometry to classic prognosticators in breast cancerCancer, 1985
- ADJUVANT CMF CHEMOTHERAPY IN OPERABLE BREAST CANCER: TEN YEARS LATERThe Lancet, 1985
- Relation of estrogen and/or progesterone receptor content of breast cancer to patient outcome following adjuvant chemotherapyBreast Cancer Research and Treatment, 1983
- Progesterone Receptors as a Prognostic Factor in Stage II Breast CancerNew England Journal of Medicine, 1983
- Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry.Journal of Histochemistry & Cytochemistry, 1983
- Pathologic findings from the national surgical adjuvant breast project.VIII. Relationship of chemotherapeutic responsiveness to tumor differentiationCancer, 1983
- The lack of relationship between estrogen receptor status and response to chemotherapyCancer, 1980
- The relative importance of estrogen receptor analysis as a prognostic factor for recurrence or response to chemotherapy in women with breast cancerCancer, 1980